BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Santibanez M, Lesch C, Lin L, Berger K. Tolerability and effectiveness of 4-factor prothrombin complex concentrate (4F-PCC) for warfarin and non-warfarin reversals. Journal of Critical Care 2018;48:183-90. [DOI: 10.1016/j.jcrc.2018.08.031] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Dibiasi C, Wiegele M, Gratz J. Orthotopic liver transplantation in a patient receiving apixaban for portal vein thrombosis. J Clin Anesth 2019;56:41-2. [PMID: 30684925 DOI: 10.1016/j.jclinane.2019.01.020] [Reference Citation Analysis]
2 Hormese M, Littler A, Doane B, Glowacki N, Khimani A, Vivacqua N, Rudenberg K. Comparison of high- and low-dose 4-factor prothrombin complex concentrate for the emergent reversal of oral Factor Xa inhibitors. J Thromb Thrombolysis 2021. [PMID: 33725284 DOI: 10.1007/s11239-021-02412-8] [Reference Citation Analysis]
3 Brown CS, Scott RA, Sridharan M, Rabinstein AA. Real-world utilization of andexanet alfa. The American Journal of Emergency Medicine 2020;38:810-4. [DOI: 10.1016/j.ajem.2019.12.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
4 Dietrich SK, Rowe S, Cocchio CA, Harmon AJ, Nerenberg SF, Blankenship PS. Comparison of 3 Different Prothrombin Complex Concentrate Regimens for Emergent Warfarin Reversal: PCCWaR Study. Ann Pharmacother 2021;55:980-7. [PMID: 33305592 DOI: 10.1177/1060028020978568] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Panos NG, Cook AM, John S, Jones GM, Kelly H, Choi RK, Kalaria N, Rosini JM, Jones M, Rehman M, Ross PM, Motley B, Delibert S, George BP, Andrews CM, Neyens RR, Martin R, Schomer KJ, Armahizer MJ, Pajoumand M, May CC, Smetana KS, Strohm T, Hamm C, Jakubowski L, Keegan SP, Srinivasan V, Burdick CJ, Martinez OJ, Bahrassa F, May ST, Sowers KA, Lin EI, Rohaley DJ, Mackey J, Wetmore LL, Frick C, Thatikunta M, Urben L, Ammar AA, Owusu KA, Nguyen K, Erdman MJ, Gilbert BW, Demott JM, Peksa GD, Tobias PE, Da Silva I, Mahmoud LN, Sheahan B, Gennaro AG, Pizzi MA, Brophy GM, Rivet DJ, Strein M, Arandela K, Hellerslia V, Caylor MM. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates. Circulation 2020;141:1681-9. [DOI: 10.1161/circulationaha.120.045769] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 14.0] [Reference Citation Analysis]
6 Milling TJ, Pollack CV. A review of guidelines on anticoagulation reversal across different clinical scenarios – Is there a general consensus? The American Journal of Emergency Medicine 2020;38:1890-903. [DOI: 10.1016/j.ajem.2020.05.086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Erdoes G, Koster A, Ortmann E, Meesters MI, Bolliger D, Baryshnikova E, Martinez Lopez De Arroyabe B, Ahmed A, Lance MD, Ranucci M, von Heymann C, Agarwal S, Ravn HB. A European consensus statement on the use of four-factor prothrombin complex concentrate for cardiac and non-cardiac surgical patients. Anaesthesia 2021;76:381-92. [PMID: 32681570 DOI: 10.1111/anae.15181] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
8 Sobolewski KA, Brophy A, Choi SC, Opsha Y. Real-World Observational Review of Andexanet Alfa Prescribing and Utilization Outcomes at a Community Teaching Hospital. Crit Care Explor 2021;3:e0356. [PMID: 33834167 DOI: 10.1097/CCE.0000000000000356] [Reference Citation Analysis]
9 Gómez-Outes A, Alcubilla P, Calvo-Rojas G, Terleira-Fernández AI, Suárez-Gea ML, Lecumberri R, Vargas-Castrillón E. Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants. J Am Coll Cardiol 2021;77:2987-3001. [PMID: 34140101 DOI: 10.1016/j.jacc.2021.04.061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Gilbert BW, Reeder JA, Alkhalifah MA, Moran DA, Corvino MA. Throwing it in reverse: An update on reversal of oral factor Xa inhibitors. The American Journal of Emergency Medicine 2019;37:1978-80. [DOI: 10.1016/j.ajem.2019.04.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
11 Ghosh S, Krege W, Doerr B, Mischnik M, Pragst I, Dickneite G, Herzog E. Evaluation of the prothrombotic potential of four-factor prothrombin complex concentrate (4F-PCC) in animal models. PLoS One 2021;16:e0258192. [PMID: 34614035 DOI: 10.1371/journal.pone.0258192] [Reference Citation Analysis]
12 Ostermann H, von Heymann C. Prothrombin complex concentrate for vitamin K antagonist reversal in acute bleeding settings: efficacy and safety. Expert Rev Hematol 2019;12:525-40. [PMID: 31159607 DOI: 10.1080/17474086.2019.1624520] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Zheng Y, Tormey CA. The use of 4F-PCC to correct direct oral anticoagulant-induced coagulopathy: An observational analysis. Transfus Med 2020;30:304-7. [PMID: 32342588 DOI: 10.1111/tme.12683] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Frontera JA, Bhatt P, Lalchan R, Yaghi S, Ahuja T, Papadopoulos J, Joset D. Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage. J Thromb Thrombolysis 2020;49:121-31. [DOI: 10.1007/s11239-019-01973-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 7.7] [Reference Citation Analysis]
15 Dietrich SK, Mixon M, Holowatyj M, Werth JC, Delgado SA, Mascolo NE, Meister ER, Zoucha SM, Trujillo TC. Multi-centered evaluation of a novel fixed-dose four-factor prothrombin complex concentrate protocol for warfarin reversal. The American Journal of Emergency Medicine 2020;38:2096-100. [DOI: 10.1016/j.ajem.2020.06.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
16 Rali P, Gangemi A, Moores A, Mohrien K, Moores L. Direct-Acting Oral Anticoagulants in Critically Ill Patients. Chest 2019;156:604-18. [PMID: 31251908 DOI: 10.1016/j.chest.2019.05.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Berger K, Santibañez M, Lin L, Lesch CA. A Low-Dose 4F-PCC Protocol for DOAC-Associated Intracranial Hemorrhage. J Intensive Care Med 2020;35:1203-8. [DOI: 10.1177/0885066619840992] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
18 Procopio GL, Jain RP, Tompkins DM, Perez JM, Bicking K. Impact of a pharmacist driven anticoagulation reversal program at a large academic medical center. J Thromb Thrombolysis 2021. [PMID: 34097227 DOI: 10.1007/s11239-021-02491-7] [Reference Citation Analysis]
19 Smith MN, Deloney L, Carter C, Weant KA, Eriksson EA. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study. J Thromb Thrombolysis 2019;48:250-5. [DOI: 10.1007/s11239-019-01846-5] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 15.0] [Reference Citation Analysis]
20 Nederpelt CJ, Naar L, Sylvester KW, Barra ME, Roberts RJ, Velmahos GC, Kaafarani HMA, Rosenthal MG, King DR. Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa. J Thromb Haemost 2020;18:2532-41. [PMID: 32738161 DOI: 10.1111/jth.15031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
21 Swieton J, Miklosz J, Yusa SI, Szczubialka K, Pawlak D, Mogielnicki A, Kalaska B. Reversal Activity and Toxicity of Heparin-Binding Copolymer after Subcutaneous Administration of Enoxaparin in Mice. Int J Mol Sci 2021;22:11149. [PMID: 34681808 DOI: 10.3390/ijms222011149] [Reference Citation Analysis]
22 Jennings DL, Rimsans J, Connors JM. Prothrombin Complex Concentrate for Warfarin Reversal in Patients with Continuous-Flow Left Ventricular Assist Devices: A Narrative Review. ASAIO J. 2020;66:482-488. [PMID: 31192853 DOI: 10.1097/mat.0000000000001021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Faulkner H, Chakankar S, Mammi M, Lo JYT, Doucette J, Al-Otaibi N, Abboud J, Le A, Mekary RA, Bunevicius A. Safety and efficacy of prothrombin complex concentrate (PCC) for anticoagulation reversal in patients undergoing urgent neurosurgical procedures: a systematic review and metaanalysis. Neurosurg Rev 2021;44:1921-31. [PMID: 33009989 DOI: 10.1007/s10143-020-01406-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]